drugset
drugset / Trial / NCT06474481

Zanubrutinib and G-CHOP in Untreated Intermediate-high Risk Follicular Lymphoma

NCT06474481 ↗

Phase 2 Not yet recruiting 30 enrolled Tianjin Medical University Cancer Institute and Hospital
NaSingle-groupOpen-labelTreatment

Summary

:This is a an open-label, single-arm study to evaluate the efficacy and safety of zanubrutinib and G-CHOP in untreated Intermediate-high risk Follicular Lymphoma patients.

Timeline

Start
2024-07
Primary completion
2027-12
Completion
2029-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Zanubrutinib Small molecule 160 mg Oral
Background Cyclophosphamide Other / unclassified 750 mg/m2 Intravenous
Background Doxorubicin Other / unclassified 50 mg/m2 Intravenous
Background Obinutuzumab Monoclonal antibody 1000 mg Intravenous
Background Prednisone Other / unclassified 100 mg Oral
Background Vincristine Small molecule 1.4 mg/m2 Intravenous

Indications

No indication recorded.